The Future of Antibody Technology: Characterizing Novel Formats for Therapeutics

Broadcast Date: November 17, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Many approved, full-length antibodies are of the immunoglobulin G (IgG) type, specifically IgG1, IgG2, or IgG4 subclasses. However, emerging non-traditional antibody formats are more efficacious and capable of reaching new targets, including crossing the blood–brain barrier. Formats that retain the basic structure of an IgG may inherit their pharmacokinetic properties, but novel constructs that lack the fragment crystallizable region (Fc) region of the antibody can have shorter half-lives. In therapeutics, smaller antibody formats such as single-chain fragment variables (scFv), nanobodies, or other scaffolds that can reach hidden targets or act as intrabodies to target intracellular antigens must strike a balance between efficacy and half-life.

In this GEN Learning Lab, Anna Moberg will discuss applications for screening and characterizing antibody and antibody fragments in pure or complex samples. During her presentation, she will introduce the Cytiva Biacore system, which uses surface plasmon resonance (SPR), a label-free and biophysical technology for characterizing antibodies. Mrs. Moberg will discuss how the technology can be used to monitor and track molecular interactions in real-time for drug discovery, quality control, and drug release testing.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.